<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82660">
  <stage>Registered</stage>
  <submitdate>7/03/2008</submitdate>
  <approvaldate>20/03/2008</approvaldate>
  <actrnumber>ACTRN12608000144314</actrnumber>
  <trial_identification>
    <studytitle>Can a Culture of Healthy Bacteria be used to Treat Arthritis?</studytitle>
    <scientifictitle>A Double Blind Randomised Controlled Trial of an Orally administered Probiotic in the Treatment of Spondyloarthritis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Spondyloarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Trial intervention is a Probiotic provided by BLIS Technologies Dunedin.
Probiotic on trial is a preparation of live bacteria in powdered form containing 100 million Streptococcus salivarius K12, 400 million Lactobacillus acidophilus L10, 400 million Bifidobacterium Lactis B94 per dose. Each participant in the active group takes 2 small teaspoons daily for 3 months.</interventions>
    <comparator>Subjects with spondyloarthrits receiving Placebo (trehalose, maltodextrin and vanilla flavour).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>European League Against Rheumatism (EULAR) Assesments in Ankylosing Spondylitis (ASAS) response criteria for Ankylosing spondylitis intervention trials</outcome>
      <timepoint>0, 1, 3, 4 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Bath Ankylosing spondylitis disease activity index (BASDAI)</outcome>
      <timepoint>0, 1 , 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bath Ankylosing spondylitis functional index (BASFI)</outcome>
      <timepoint>0, 1 , 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bath Ankylosing spondylitis metrology index (BASMI)</outcome>
      <timepoint>0, 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bath Ankylosing spondylitis patient global score (BASG)</outcome>
      <timepoint>0, 1 , 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral tender and swollen joint count</outcome>
      <timepoint>0, 1 , 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maastricht Ankylosing Spondylitis Enthesitis score (MASES) enthesitis index</outcome>
      <timepoint>0, 1 , 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C-reactive protein (CRP)</outcome>
      <timepoint>0, 1 , 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Multidimensional assesment of fatigue (MAF) index</outcome>
      <timepoint>0, 3, 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ankylosing spondylitis Quality of Life (ASQol) assesment</outcome>
      <timepoint>0, 1 , 3, 4 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Modified New York criteria for Ankylosing spondylitis OR European Spondyloarthropathy study group (ESSG) criteria for spondyloarthritis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy, severe immunosupression, active inflammatory bowel disease, current gastrointestinal infection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects are identified from a database of patients with spondyloarthritis and invited to participate. Subjects are randomised using random number generation by Clinical trials manager at BLIS technologies.  Assessment and enrolment are performed by blinded assessor who  allocates the coded probiotic. Codes are held by clinical trials manager who is not involved in the assessments.</concealment>
    <sequence>Permuted block randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>10/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>Great King Street
Dunedin</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Arthritis New Zealand</fundingname>
      <fundingaddress>166 Featherston street
Wellington</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Bacteriocin Like Inhibitory Substances (BLIS) Technologies</sponsorname>
      <sponsoraddress>Center for Innovation
University of Otago
87 St David Street
Dunedin</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We propose a trial of a potential treatment for Spondyloarthritis - a common form of arthritis in New Zealand which particularly affects young adults.  We will use a probiotic agent (a culture of healthy bacteria) which can modify the bacterial environment in the human intestinal tract. We have previously demonstrated a disturbed bowel bacterial flora in patients with spondyloarthritis, who are known to have an inflamed leaky gut. By using a probiotic we hope to reverse the inflammatory process in the gut and improve the resulting arthritis. This is a novel approach, using a product developed by a local biotechnology company, which is a safe and potentially effective therapy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Lower South Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
229 Moray Place
PO Box 5849
Dunedin</ethicaddress>
      <ethicapprovaldate />
      <hrec>LRS/06/02/008</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Simon Stebbings</name>
      <address>Dunedin School of Medicine
Great King Street
Dunedin</address>
      <phone>+ 64 3 4740999</phone>
      <fax />
      <email>simon.stebbings@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Simon Stebbings</name>
      <address>Department of Medical and Surgical Sciences
Dunedin School of Medicine
Great King Street
Dunedin</address>
      <phone>+ 64 3 4740999</phone>
      <fax>+ 64 3 4747641</fax>
      <email>simon.stebbings@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Simon Stebbings</name>
      <address>Dunedin School of Medicine
Great King Street
Dunedin</address>
      <phone>+ 64 3 4740999</phone>
      <fax />
      <email>simon.stebbings@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>